Skip to main content
. 2017;18(8):2171–2177. doi: 10.22034/APJCP.2017.18.8.2171

Table 3.

Analysis of the Prognostic Role of VEGFAxxx and VEGFA165b Expression in HNSCC

12-month disease-free survival (%) p value 12-month overall survival (%) p value
VEGFAxxx
Overexpression 75 0.963 100 0.902
Down expression 81 90
VEGFA165b
Overexpression 75 0.687 100 0.91
Down expression 79 100